Overview
- Authors:
-
-
Peter K. Gessner
-
School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, USA
-
Teresa Gessner
-
Roswell Park Graduate Division, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, USA
Access this book
Other ways to access
Table of contents (16 chapters)
-
-
- Peter K. Gessner, Teresa Gessner
Pages 1-6
-
- Peter K. Gessner, Teresa Gessner
Pages 7-12
-
- Peter K. Gessner, Teresa Gessner
Pages 13-19
-
- Peter K. Gessner, Teresa Gessner
Pages 21-28
-
- Peter K. Gessner, Teresa Gessner
Pages 29-42
-
- Peter K. Gessner, Teresa Gessner
Pages 43-63
-
- Peter K. Gessner, Teresa Gessner
Pages 65-93
-
- Peter K. Gessner, Teresa Gessner
Pages 95-135
-
- Peter K. Gessner, Teresa Gessner
Pages 137-166
-
- Peter K. Gessner, Teresa Gessner
Pages 167-203
-
- Peter K. Gessner, Teresa Gessner
Pages 205-246
-
- Peter K. Gessner, Teresa Gessner
Pages 247-277
-
- Peter K. Gessner, Teresa Gessner
Pages 279-293
-
- Peter K. Gessner, Teresa Gessner
Pages 295-312
-
- Peter K. Gessner, Teresa Gessner
Pages 313-334
-
- Peter K. Gessner, Teresa Gessner
Pages 335-345
-
Back Matter
Pages 347-452
About this book
This book is aimed at those in the biomedical community that are interested in the therapeutic applications, pharmacology, biochemistry, toxicology and pharmacokinetics of the title compounds. Recent findings regarding the ability of diethyldithiocarbamate (ditiocarb, Imuthiol®) to delay the progression of HN infections and AIDS, the discovery of its potential as a rescue agent in cancer chemotherapy, and the identification of disulfiram (Antabuse®) regimens that allow alcoholics to achieve abstinence of many months' duration have made writing this book an exciting experience. At the same time the fact that the two drugs differ substantially in their pharmacological effects in spite of their easy interconvertibility has rendered the writing intellec tually challenging. Diethyldithiocarbamate, an agent seemingly less toxic than aspirin, rivals it in the multiplicity and diversity of its pharmacological proper ties. Notable among these are the manyfold potent immunostimulant effects, and though most of these involve effects on T -cells, the mechanism of diethyldithiocarbamate's action remains far from clear. The drug is also a potent chelator of heavy metals and this has led to a number of clinical applications. As might be expected, it inhibits several important enzymes. Further, it is one of the most effective radioprotective agents; it also protects organisms against a variety of toxic agents.
Reviews
...a well written, detailed publication on literally everything the reader would wish to know about disulfiram and its metabolite - British Journal of Psychiatry; This well written and carefully edited volume deserves the interest of toxicologists, pharmacologists, immunologists, biochemists and clinicians. Journal of Applied Toxicology; It is hoped that clinicians and behavioral scientists have read this book for their own education and also to appreciate the advances made in the biochemical pharmacology of DSSD and SSH. This book should capture the interest of medicinal chemists and pharmacologists who are engaged in research in cancer, immunomodulation, HIV, and heavy metal toxicity. Selected chapters are must reading for biomedical scientists pursuing alcoholism research. Journal of Medicinal Chemistry
Authors and Affiliations
-
School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, USA
Peter K. Gessner
-
Roswell Park Graduate Division, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, USA
Teresa Gessner
